As stakeholders debate fair market value in clinical trial budgeting, a new task force works to align sponsors, CROs, and ...

Phase II CONFIDENCE study data reveal that simultaneous initiation of Kerendia and Jardiance significantly improves UACR and ...

Results from the Phase Ib/II CARTITUDE-1 trial demonstrated that a single infusion of Carvykti delivered durable, ...

In the Phase III VISIONARY study, sibeprenlimab, an investigational monoclonal antibody, showed a 51.2% reduction in ...

New data from the IRAKLIA and IZALCO trials, presented at the 2025 ASCO Annual Meeting, demonstrate that subcutaneous ...

Case study highlights how clinical operations teams can overcome complex regulatory and operational hurdles to finish a trial ...

As biotech innovation accelerates, the clinical research workforce is rapidly eroding—threatening the future of drug ...

Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

In this video interview, Jim Kremidas, executive director, Association for MultiSite Research Corporations (AMRC), discusses ...

In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease ...

In this video interview, Jim Kremidas, executive director, Association for MultiSite Research Corporations (AMRC), talks ...

Despite positive results from a Phase I/II trial of its investigational pandemic influenza vaccine, mRNA-1018, Moderna’s ...